Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Oncolytics Biotech Inc T.ONC

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer.
Price: $0.90 Volume: 299,675
Change: $-0.01 % Change: -1.10%
Day High/Low: 0.93/0.86 52 Week High/Low: 1.82/0.445
Last Traded: April 24, 2015 11:59 Transaction Volume: 1000
Open: 0.93 Previous Close: 0.91
Bid: 0.90 Ask: 0.91
Bid Size: 4000 Ask Size: 12000
Market Cap: 98.7m Shares Out: 109.7m
PE Ratio: N/A Dividend Yield: N/A


Canadian Biotech comes back to life: A buyer's guide

Everything you could ever want to know about biotech, biomed and bio investments up north.

Tony Pullen   January 21, 2014
0 stars

Latest Bullboard Posts

  • Minutes of the EMA meeting

    0 stars

    The Committee agreed that the condition, pancreatic cancer, is a distinct medical entity and meets the criteria for orphan designation. ...

    2.5 stars

  • RE: Renmark Calgary meeting

    0 stars

    Rok1’s summary of the Renmark Calgary meeting is very informative. The two points that stand out for me are the existing 1 million doses...

    1.5 stars

  • Renmark Calgary meeting

    5 stars

    I found this on the V2 board. The poster's financial advisor attended the meeting..... Please remember that these are my notes of a...

    2.5 stars

  • 2015 AACR

    5 stars

    Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 2015 AACR Annual Meeting CALGARY, April 20, 2015 /CNW/...

    2 stars

  • Orphan Status a two-edged sword

    0 stars

    Oncolytics Biotech has a very promising product, and from what I can tell, are still very much in the running if thier funding can hold...

    0 stars